Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602290 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 181
- Enrollment target
NCT00602290: Completed Phase 4 study, sponsored by University of California, Los Angeles.
NCT00602290 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 181 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00602290, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 181 participants
- Enrollment target
Study Summary
This study will evaluate the safety and effectiveness of methylphenidate in improving cognition and function in older adults with depression.
Primary Outcome
The Hamilton Depression Rating Scale (HDRS) is a 24-item depression scale and the total score is summed with a minimum score=0 and maximum score=76. There are no subscales and the higher values represent a worse outcome. Outcomes are measured and defined as follows: 1) Response will be defined as HDRS scores of 10 or less; 2) Sustained response will be defined as maintained response at week 16; 4) Remission will be defined as HDRS scores of 6 or less.
Interventions
- DRUG Placebo
- DRUG Citalopram
- DRUG Methylphenidate (MPH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2008-02 |
| Est. Completion | 2013-02 |
| Phase | Phase 4 |
What the finished NCT00602290 record still lists
NCT00602290 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00602290 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00602290 about?
NCT00602290 is a clinical study titled "Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression". This study will evaluate the safety and effectiveness of methylphenidate in improving cognition and function in older adults with depression.
What is the current status of trial NCT00602290?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 181 participants. The study started on 2008-02. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00602290?
The interventions under investigation include: Placebo (DRUG), Citalopram (DRUG), Methylphenidate (MPH) (DRUG).
Who is sponsoring clinical trial NCT00602290?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00602290's enrollment target sits among peer trials
181 464th of 2000 higher than 1,535 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia